Children, Myopia
Conditions
Keywords
atropine
Brief summary
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic. ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising. The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017. Few clinical data have been published so far concerning the French population. The investigators would like to build a database so that the investigators can publish our results and share our experience.
Interventions
OTHERdata collection
* Demographic data: age, sex * Ophthalmological history: refraction of parents, previous refractions * Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics * Potential undesirable events (halos, photophobia...)
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children with active myopia treated with ATROPINE 0.01% eye drops * patient affiliated with a social security organization * agreement of both parents
Exclusion criteria
* non compliance with treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| biometrics | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| previous refractions | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| refraction of parents | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| intra-ocular pression | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| objective refraction after fog | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| cycloplegia with SKIACOL | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| slit lamp | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
| dilated eye exam | every 6 months up to age 18 years | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| undesirable events collection | every 6 months up to age 18 years | measured the tolerance of ATROPINE 0.01% eyedrops. Number of participants with treatment-related adverse events. |
Countries
France
Contacts
Primary ContactMarie Caroline TRONE
Backup ContactMarie PEURIERE
Outcome results
None listed